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C O R O N A V I R U S
Non-neuronal expression of SARS-CoV-2 entry genes 
in the olfactory system suggests mechanisms 
underlying COVID-19–associated anosmia
David H. Brann1*, Tatsuya Tsukahara1*, Caleb Weinreb1*, Marcela Lipovsek2, 
Koen Van den Berge3,4, Boying Gong5, Rebecca Chance6, Iain C. Macaulay7, Hsin-Jung Chou6, 
Russell B. Fletcher6†, Diya Das6,8‡, Kelly Street9,10, Hector Roux de Bezieux5,11, Yoon Gi Choi12, 
Davide Risso13, Sandrine Dudoit3,5, Elizabeth Purdom3, Jonathan Mill14, Ralph Abi Hachem15, 
Hiroaki Matsunami16, Darren W. Logan17, Bradley J. Goldstein15, Matthew S. Grubb2, 
John Ngai6,12,18§, Sandeep Robert Datta1║
Altered olfactory function is a common symptom of COVID-19 (coronavirus disease 2019), but its etiology is 
unknown. A key question is whether SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; CoV-2)—the 
causal agent in COVID-19—affects olfaction directly, by infecting olfactory sensory neurons or their targets in the 
olfactory bulb, or indirectly, by perturbing support cells. Bulk and single-cell RNA sequencing revealed that sup-
port and stem cells in the human and mouse olfactory epithelium and vascular pericytes in the mouse olfactory 
bulb express angiotensin-converting enzyme 2 (ACE2), which is essential for CoV-2 cell entry. In contrast, ACE2 
was not detected in either olfactory sensory neurons or olfactory bulb neurons. Immunostaining confirmed these 
results and revealed pervasive expression of ACE2 protein in dorsally located olfactory epithelial sustentacular 
cells and mouse olfactory bulb pericytes. These findings suggest that CoV-2 infection of non-neuronal cell types 
leads to olfactory dysfunction in patients with COVID-19.
INTRODUCTION
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; 
CoV-2) is a pandemic coronavirus that causes the COVID-19 
(coronavirus disease 2019) syndrome, which can include upper 
respiratory infection (URI) symptoms, severe respiratory distress, 
acute cardiac injury, and death (1–4). CoV-2 is closely related to 
other coronaviruses, including the causal agents in pandemic SARS 
and MERS (Middle East respiratory syndrome) (SARS-CoV and 
MERS-CoV, respectively) and endemic viruses typically associated 
with mild URI syndromes (HCoV-OC43, HCoV-HKU1, HCoV-229E, 
and HCoV-NL63) (5–7). Clinical reports suggest that infection with 
CoV-2 is associated with high rates of disturbances in smell and 
taste perception, including anosmia (8–13). While many viruses 
(including coronaviruses) induce transient changes in odor perception 
due to inflammatory responses, in at least some cases, COVID-19–related 
anosmia has been reported to occur in the absence of significant nasal 
inflammation or coryzal symptoms (11, 14–16). Furthermore, recovery 
from COVID-19–related anosmia often occurs over weeks (11, 17, 18), 
while recovery from typical postviral anosmia—which is often caused 
by direct damage to olfactory sensory neurons (OSNs)—frequently 
takes months (19–21). These observations suggest that CoV-2 might 
target odor processing through mechanisms distinct from those used 
by other viruses, although the specific means through which CoV-2 
alters odor perception remains unknown.
CoV-2—like SARS-CoV—infects cells through interactions between 
its spike (S) protein and the angiotensin-converting enzyme 2 
(ACE2) protein on target cells. This interaction requires cleavage of 
the S protein, likely by the cell surface protease TMPRSS2 (transmem-
brane serine protease 2), although other proteases [such as cathepsin B 
and L (CTSB/CTSL)] may also be involved (4–6, 22–25). Other coronavi-
ruses use different cell surface receptors and proteases to facilitate 
cellular entry, including DPP4, FURIN, and HSPA5 for MERS-CoV; 
ANPEP for HCoV-229E; TMPRSS11D for SARS-CoV (in addition 
to ACE2 and TMPRSS2); and ST6GAL1 and ST3GAL4 for HCoV-
OC43 and HCoV-HKU1 (6, 26–28).
We hypothesized that identifying the specific cell types susceptible 
to direct CoV-2 infection (due to, e.g., ACE2 and TMPRSS2 expres-
sion) would provide insight into possible mechanisms through 
which COVID-19 alters smell perception. The nasal epithelium is 
divided into a respiratory epithelium (RE) and olfactory epithelium 
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(OE), whose functions and cell types differ. The nasal RE is continuous 
with the epithelium that lines much of the respiratory tract and is 
thought to humidify air as it enters the nose; main cell types include 
basal cells, ciliated cells, secretory cells (including goblet cells), and 
brush/microvillar (MV) cells (Fig. 1) (29, 30). The OE, in contrast, 
is responsible for odor detection, as it houses mature OSNs 
(mOSNs) that interact with odors via receptors localized on their 
dendritic cilia. OSNs are supported by sustentacular (SUS) cells, 
which act to structurally support sensory neurons and phagocytose 
and/or detoxify potentially damaging agents, and maintain local 
salt and water balance (31–33); MV cells and mucus-secreting 
Bowman’s gland (BG) cells also play important roles in maintaining 
OE homeostasis and function (Fig. 1) (29, 34). In addition, the OE 
contains globose basal cells (GBCs), which are primarily responsible 
for regenerating OSNs during normal epithelial turnover, and 
horizontal basal cells (HBCs), which are reserve stem cells activated 
upon tissue damage (35–37). Although studies defining the lineage 
relationships between GBCs, HBCs, and their progeny have neces-
sarily been performed in rodents, basal progenitor populations with 
similar transcriptional profiles are present in adult human OE, 
suggesting closely related homeostatic and injury-response mecha-
nisms (37, 38). Odor information is conveyed from the OE to the 
brain by OSN axons, which puncture the cribriform plate at the 
base of the skull and terminate in the olfactory bulb (OB). Within 
the OB, local circuits process olfactory information before sending 
it to higher brain centers (Fig. 1).
It has recently been demonstrated through single-cell RNA 
sequencing (RNA-seq) analysis (referred to herein as scSeq) that 
cells from the human upper airway—including nasal RE goblet and 
ciliated cells—express high levels of ACE2 and TMPRSS2, suggest-
ing that these RE cell types may serve as a viral reservoir during 
CoV-2 infection (39, 40). However, analyzed samples in these 
datasets did not include any OSNs or SUS cells, indicating that tissue 
sampling in these experiments did not include the OE (41, 42). 
Here, we query both new and previously published bulk RNA-seq 
and scSeq datasets from the olfactory system for expression of 
ACE2, TMPRSS2, and other genes implicated in coronavirus entry. 
We find that non-neuronal cells in the OE and OB, including sup-
port, stem, and perivascular cells, express CoV-2 entry–associated 
transcripts and their associated proteins, suggesting that infection 
of these non-neuronal cell types contributes to anosmia in patients 
with COVID-19.
RESULTS
Expression of CoV-2 entry genes in human OE
To determine whether genes relevant to CoV-2 entry are expressed 
in OSNs or other cell types in the human OE, we queried previously 
published bulk RNA-seq data derived from the whole olfactory 
mucosa (WOM) of macaque, marmoset, and human (43) and found 
expression of almost all CoV-2 entry–related genes in all WOM sam-
ples (fig. S1A). To identify the specific cell types in human OE that 
express ACE2, we quantified gene expression in scSeq derived from 
four human nasal biopsy samples recently reported by Durante et al. 
(38). Neither ACE2 nor TMPRSS2 was detected in mOSNs, whereas 
these genes were detected in both SUS cells and HBCs (Fig. 2, A to D, 
and fig. S1, B to E). In contrast, genes relevant to cell entry of other 
CoVs were expressed in OSNs, as well as in other OE cell types. We 
confirmed the expression of ACE2 protein via immunostaining of 
human OE biopsy tissue, which revealed expression in SUS and 
HBC cells, and an absence of ACE2 protein in OSNs (Fig. 2E and 
fig. S2). Together, these results demonstrate that SUS and olfactory 
stem cells, but not OSNs, are potentially direct targets of CoV-2 in the 
human OE.
Given that the nasopharynx is a major site of infection for CoV-2 
(10), we compared the frequency of ACE2 and TMPRSS2 expres-
sion among the cell types in the human RE and OE (38). SUS cells 
exhibited the highest frequency of ACE2 expression in the OE (2.9% 
of cells), although this frequency was slightly lower than that ob-
served in respiratory ciliated and secretory cells (3.6 and 3.9%, re-
spectively). While all HBC subtypes expressed ACE2, the frequency 
of expression of ACE2 was lower in olfactory HBCs (0.8% of cells) 
compared to respiratory HBCs (1.7% of cells) (Fig. 2D). In addition, 
all other RE cell subtypes showed higher frequencies of ACE2 and 
TMPRSS2 expression than was apparent in OE cells.
These results demonstrate the presence of key CoV-2 entry– 
related genes in specific cell types in the OE but at lower levels of 
expression than in RE isolated from the human nasal mucosa. We 
wondered whether these lower levels of expression might none-
theless be sufficient for infection by CoV-2. It was recently reported 
that the nasal RE has higher expression of CoV-2 entry genes than 
the RE that lines the trachea or lungs (44), and we therefore asked 
where the OE fell within this previously established spectrum of ex-
pression. To address this question, we developed a two-step align-
ment procedure in which we first sought to identify cell types that 
were common across the OE and RE and then leveraged gene 
expression patterns in these common cell types to normalize gene 
expression levels across all cell types in the OE and RE (Fig. 3 and 
fig. S3). This approach revealed correspondences between submucosal 
gland goblet cells in the RE and BG cells in the OE (96% mapping 
probability; see Materials and Methods) and between pulmonary 

























Fig. 1. Schematic of the nasal RE, OE, and the OB. Left: Sagittal view of the 
human nasal cavity, in which respiratory and olfactory epithelia are colored. Right: 
For each type of epithelium, a schematic of the anatomy and known major cell 
types are shown. In the OB in the brain (tan), the axons from OSNs coalesce into 
glomeruli, and mitral/tufted cells innervate these glomeruli and send olfactory 
projections to downstream olfactory areas. Glomeruli are also innervated by 
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probability; see Materials and Methods and fig. S3); after alignment, 
human OE SUS cells were found to express ACE2 and TMPRSS2 at 
levels similar to those observed in the remainder of the non-nasal 
respiratory tract (Fig. 3C) (44). As CoV-2 can infect cells in the 
lower respiratory tract (40, 45), these results are consistent with the 
possibility that specific cell types in the human OE express ACE2 at 
a level that is permissive for direct infection.
Expression of CoV-2 entry genes in mouse OE
To further explore the distribution of CoV-2 cell entry genes in the 
olfactory system, we turned to the mouse, which enables interrogative 
experiments not possible in humans. To evaluate whether mouse ex-
pression patterns correspond to those observed in the human OE, we 
examined published datasets in which RNA-seq was independently 
performed on mouse WOM and on purified populations of mOSNs 
(46–48). The CoV-2 receptor Ace2 and the protease Tmprss2 were 
expressed in WOM, as were the cathepsins Ctsb and Ctsl (Fig. 4A 
and fig. S4A) (46). However, expression of these genes (with the ex-
ception of Ctsb) was much lower, and Ace2 expression was nearly 
absent in purified OSN samples (Fig. 4A and fig. S4A, see legend for 
counts). Genes used for cell entry by other CoVs (except St3gal4) were 
also expressed in WOM, and de-enriched in purified OSNs. The de- 
enrichment of Ace2 and Tmprss2 in OSNs relative to WOM was also 





















































































































































































Fig. 2. Coronavirus cell entry–related genes are expressed in human RE and OE but are not detected in human OSNs. (A) UMAP representation of cell types in 
human nasal biopsy scSeq data from Durante et al. (38). Each dot represents an individual cell, colored by cell type. Resp., respiratory; OEC, olfactory ensheathing cell; SMC, 
smooth muscle cell; NK, natural killer. (B) UMAP representations of 865 detected immature (GNG8) and mature (GNG13) OSNs. Neither ACE2 nor TMPRSS2 is detected in 
either population of OSNs. The color represents the normalized expression level for each gene (number of UMIs for a given gene divided by the total number of UMIs for 
each cell). (C) UMAP representations of all cells, depicting the normalized expression of CoV-2–related genes ACE2 and TMPRSS2, as well as several cell-type markers. ACE2 
and TMPRSS2 are expressed in respiratory and olfactory cell types but not in OSNs. ACE2 and TMPRSS2 are detected in HBC (KRT5) and SUS (CYP2A13) cells, as well as other 
respiratory epithelial cell types, including respiratory ciliated (FOXJ1) cells. (D) Percentage of cells expressing ACE2 and TMPRSS2. ACE2 was not detected in any OSNs, 
but was observed in SUS cells and HBCs, among other olfactory and respiratory epithelial cell types. Olfactory and respiratory cell types are shown separately. ACE2 and 
TMPRSS2 were also significantly coexpressed (odds ratio, 7.088; P = 3.74 × 10−57, Fisher’s exact test). (E) ACE2 immunostaining of a human olfactory mucosal biopsy 
(taken from a 28-year-old female). ACE2 protein (green) is detected in SUS cells and KRT5-positive HBCs (red; white arrowhead). Nuclei were stained with 4′,6-diamidino- 
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The presence of Ace2 and Tmprss2 transcripts in mouse WOM 
and their (near total) absence in purified OSNs suggest that the mo-
lecular components that enable CoV-2 entry into cells are expressed 
in non-neuronal cell types in the mouse nasal epithelium. To iden-
tify the specific cell types that express Ace2 and Tmprss2, we per-
formed scSeq (via Drop-seq; see Materials and Methods) on mouse 
WOM (Fig. 4B). These results were consistent with observations 
made in the human epithelium: Ace2 and Tmprss2 were expressed 
in a fraction of SUS and BG cells and a very small fraction of stem 
cells but not in OSNs (zero of 17,666 identified mOSNs; Fig. 4C and 
fig. S4, C and D). Of note, only dorsally located SUS cells, which 
express the markers Sult1c1 and Acsm4, were positive for Ace2 (Fig. 4D 
and fig. S4, D and E). Based upon this observation, we reanalyzed the 
human OE scSeq data, which revealed that all positive SUS cells ex-
pressed genetic markers associated with the dorsal epithelium (fig. S1D). 
An independent mouse scSeq dataset (obtained using the 10x Chro-
mium platform; see Materials and Methods) confirmed that OSNs 
did not express Ace2 (2 of 28,769 mOSNs were positive for Ace2), 
while expression was observed in a fraction of BG cells and HBCs 
(fig. S5 and see Materials and Methods). Expression in SUS cells was not 
observed in this dataset, which included relatively few dorsal SUS cells 
(a possible consequence of the specific cell isolation procedure asso-
ciated with the 10x Chromium platform; compare fig. S5C and Fig. 4D).
Staining of the mouse WOM with anti-ACE2 antibodies confirmed 
that ACE2 protein is expressed in SUS cells and is specifically localized 
to the SUS cell microvilli (Fig. 5). ACE2+ SUS cells were identified 
exclusively within the dorsal subregion of the OE; critically, within that 
region, many (and possibly all) SUS cells expressed ACE2 (Fig. 5, B to E). 
Staining was also observed in BG cells, but not in OSNs, and in subsets 
of RE cells (Fig. 5, F and G). Together, these data demonstrate that 
ACE2 is expressed by SUS cells that specifically reside in the dorsal 
epithelium in both mouse and human.
Expression of CoV-2 entry genes in injured mouse OE
Viral injury can lead to broad changes in OE physiology that 
are accompanied by recruitment of stem cell populations tasked 
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Fig. 3. Coronavirus cell entry–related genes are expressed at comparable levels across respiratory and olfactory epithelial datasets. (A) Schematic of the 
mapping strategy used to identify similar cell types across datasets, applied to a toy example. Each cell type from dataset 1 is mapped to cell types from dataset 2. From 
left to right: Each dataset 1 cell voted on its five most similar cells in dataset 2; the total number of votes cast for each dataset 2 cell type was quantified; and vote totals 
were Z-scored against 1000 shuffles where cell-type labels were permutated. (B) Mapping was performed bidirectionally between the Deprez et al. (41) and Durante et al. 
(38) datasets, and the mapping Z scores in each direction are compared. Top: The set of cell-type correspondences with high Z scores (>25) in both directions are colored 
red. Bottom: The set of cell-type correspondences with high bidirectional mappings shown in red in top panel are highlighted in yellow. (C) Gene expression across cell 
types and tissues in Durante et al. (top) and Deprez et al. (bottom). Each gene is normalized to its maximum value across all tissues. Gene expression from Durante et al. 
was normalized to that in Deprez et al. to enable comparisons (see Materials and Methods and fig. S3). The tissues correspond to the indicated positions along the airway 
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with regenerating the epithelium (35, 37, 49). To characterize the 
distribution of Ace2 expression under similar circumstances, we 
injured the OE by treating mice with methimazole (which ablates 
both support cells and OSNs) and then used a previously estab-
lished lineage-tracing protocol to perform scSeq on HBCs and their 
descendants during subsequent regeneration (see Materials and 
Methods) (36). This analysis revealed that after injury, Ace2 and 
Tmprss2 are expressed in subsets of SUS cells and HBCs, as well 
as in the activated HBCs that serve to regenerate the epithelium 
(Fig. 6, A to C, and fig. S6A; note that activated HBCs express Ace2 
at higher levels than resting HBCs). Analysis of the Ace2+ SUS cell 
population revealed expression of dorsal epithelial markers (Fig. 6D). 
To validate these results, we reanalyzed a similar lineage-tracing 
dataset in which identified HBCs, and their progeny were subject 
to Smart-seq2–based deep sequencing, which is more sensitive than 
droplet- based scSeq methods (36). In this dataset, Ace2 was detected 
in more than 0.7% of GBCs, nearly 2% of activated HBCs and nearly 
3% of SUS cells, but was not detected in OSNs (fig. S6B). Immuno-
staining with anti-ACE2 antibodies confirmed that ACE2 protein 
was present in activated stem cells under these regeneration condi-
tions (Fig. 6E). These results demonstrate that activated stem cells 
recruited during injury express ACE2 and do so at higher levels 
than those in resting stem cells.
Expression of CoV-2 entry genes in mouse OB
Given the potential for the RE and OE in the nasal cavity to be 
directly infected with CoV-2, we assessed the expression of Ace2 
and other CoV-2 entry genes in the mouse OB, which is directly 
connected to OSNs via cranial nerve I (CN I); in principle, alter-
ations in OB function could cause anosmia independently of 
functional changes in the OE. To do so, we performed scSeq (using 
Drop-seq; see Materials and Methods) on the mouse OB and merged 
these data with a previously published OB scSeq analysis, yielding a 
dataset with nearly 50,000 single cells (see Materials and Methods) 
(50). This analysis revealed that Ace2 expression was absent from 
OB neurons and, instead, was observed only in vascular cells, pre-
dominantly in pericytes, which are involved in blood pressure reg-
ulation, maintenance of the blood-brain barrier, and inflammatory 
responses (Fig. 7, A to D, and figs. S7 and S8) (51). Although other 
potential CoV proteases were expressed in the OB, Tmprss2 was 
not expressed.
We also performed Smart-seq2–based deep sequencing of single 
OB dopaminergic juxtaglomerular neurons, a population of local 
interneurons in the OB glomerular layer that (similar to tufted cells) 
can receive direct monosynaptic input from nasal OSNs (Fig. 7E, 
fig. S9, and see Materials and Methods); these experiments confirmed 





















































































































































































































Fig. 4. ACE2 is expressed in the mouse nasal epithelium but not in OSNs. (A) Log2 fold change (FC) in mean across-replicate gene expression between OSNs and WOM 
for CoV-related genes and cell-type markers, data from Saraiva et al. (46). (B) UMAP representation of scSeq data from the WOM, colored by cell types. INP, immediate 
neural precursor. (C) Percentage of cells expressing Ace2 and Tmprss2 in olfactory and respiratory cell types in the WOM (Drop-seq) dataset. Detection was considered 
positive if any transcripts (UMIs) were expressed for a given gene. SUS cells from dorsal and ventral zones are quantified separately. Ace2 is detected in dorsal SUS, BG, 
HBCs, and respiratory cell types. (D) UMAP representation of SUS cells, with expression of CoV-2–related genes Ace2 and Tmprss2, as well as marker genes for SUS (both 
pan-SUS marker Cbr2 and dorsal-specific marker Sult1c1) indicated. The color represents the normalized expression level for each gene (number of UMIs for a given gene 
divided by the total number of UMIs for each cell; in this plot, Ace2 expression is binarized for visualization purposes). Ace2+ SUS cells are found within the dorsal Sult1c1+ 
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Immunostaining in the OB revealed that blood vessels expressed 
high levels of ACE2 protein, particularly in pericytes; nearly all 
pericytes exhibited some degree of staining with ACE2 antibodies. 
Consistent with the scSeq results, staining was not observed in any 
neuronal cell type (Fig. 7, F and G). These observations may also hold 
true for at least some other brain regions, as reanalysis of 10 deeply 
sequenced scSeq datasets from different regions of the nervous sys-
tem demonstrated that Ace2 and Tmprss2 expression is almost 
completely absent from neurons, consistent with prior immuno-
staining results (fig. S10) (52, 53). Given the extensive similarities 
detailed above in expression patterns for ACE2 and TMPRSS2 in 
the mouse and human, these findings (from mouse experiments) 
suggest that OB neurons are likely not a primary site of infection, 
but that vascular pericytes may be sensitive to CoV-2.
DISCUSSION
Here, we show that subsets of OE SUS cells, HBCs, and BG cells in 
both mouse and human samples express the CoV-2 receptor ACE2 
and the S protein protease TMPRSS2. Human OE SUS cells ex-
press these genes at levels comparable to those observed in lung 
cells. In contrast, we failed to detect ACE2 expression in human or 
mouse OSNs at either the transcript or protein levels. Similarly, 
mouse vascular pericytes in the OB express ACE2, while we did not 
detect ACE2 in OB neurons. Thus, primary infection of non-neuronal 
cell types—rather than sensory or bulb neurons—may be respon-
sible for anosmia and related disturbances in odor perception in 
patients with COVID-19.
The identification of non-neuronal cell types in the OE and OB 
susceptible to CoV-2 infection suggests four possible, non-mutually 
exclusive mechanisms for the acute loss of smell reported in 
patients with COVID-19. First, local infection of support and vascular 
cells in the nose and bulb could cause significant inflammatory 
responses (including cytokine release) whose downstream effects 
could block effective odor conduction or alter the function of OSNs 
or OB neurons (14, 54). Second, damage to support cells (which are 
responsible for local water and ion balance) could indirectly influ-
ence signaling from OSNs to the brain (55). Third, damage to SUS 
cells and BG cells in mouse models can lead to OSN death, which in 
turn could abrogate smell perception (56). Last, vascular damage 
could lead to hypoperfusion and inflammation leading to changes 
in OB function.
Although scSeq revealed ACE2 transcripts in only a subset of OE 
cells, this low level of observed expression matches or exceeds that 
observed in respiratory cell types that are infected by CoV-2 in pa-





















Fig. 5. ACE2 protein is detected in the mouse OE and RE. (A) ACE2 immunostaining of mouse main OE. As shown in this coronal section, ACE2 protein is detected in the 
dorsal zone and RE. The punctate Ace2 staining beneath the epithelial layer is likely associated with vasculature. Scale bar, 500 m. Arrowheads depict the edges of ACE2 
expression, corresponding to the presumptive dorsal zone [confirmed in (C)]. Dashed boxes indicate the areas shown in (B) and (G) (left). D, dorsal; L, lateral; 
M, medial; V, ventral. (B) ACE2 protein is detected in the dorsal zone of the OE. Scale bar, 50 m. (C) Dorsal zone–specific expression of ACE2 in the OE was confirmed by 
costaining with NQO1, a protein expressed in dorsal zone OSNs. Scale bar, 50 m. (D) ACE2 signal in dorsal OE does not overlap with the cilia of OSNs, as visualized by 
CNGA2. Scale bar, 50 m. (E) High-magnification image of the apical end of the OE reveals that ACE2 signal is localized at the tip of villi of SUS cells, visualized by phalloidin 
(F-actin), but does not overlap with cilia of OSNs, as visualized by acetylated tubulin (Ac. Tubulin). Scale bar, 10 m. (F) BGs, which span from the lamina propria to the 
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Fig. 6. ACE2 is expressed in the mouse nasal epithelium in an injury model. (A) UMAP representation of data from an scSeq HBC lineage dataset, which includes 
several time points after epithelial injury induced by methimazole. HBC*, activated or cycling HBCs. (B) UMAP representation of CoV-2–related genes Ace2 and Tmprss2, 
as well as marker genes for the HBC-derived cell types. The color represents normalized expression (number of UMIs for a given gene divided by the total number of UMIs 
for each cell). (C) Percentage of cells expressing Ace2 and Tmprss2. Ace2 is detected in SUS cells, HBCs, activated/cycling HBCs, and respiratory cells. (D) UMAP representation of 
all SUS cells, indicating the normalized expression of CoV-2–related genes Ace2 and Tmprss2, as well as SUS (Ermn) cell markers. Ace2+ SUS cells are largely a subset 
of dorsal SUS cells, as identified via the expression of Sult1c1. Sult1c1+ SUS cells have higher levels of Ace2 (P = 1.87 × 10−3, Mann-Whitney test), and Ace2+ SUS cells have 
higher levels of Sult1c1 (P = 8.06 × 10−7, Mann-Whitney test). (E) ACE2 immunostaining of mouse nasal epithelium after methimazole treatment, together with cycling cell 
marker Ki67 and HBC marker KRT5. Top: At 48 hours after treatment, ACE2 signal is detected in Ki67+/KRT5+-activated HBCs. Bottom: At 96 hours after treatment, ACE2 
signal is observed at the apical surface of Ki67+ cells. Some ACE2+ cells express low levels of the HBC marker KRT5 and have immunostaining patterns similar to that of 
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Fig. 7. Expression of coronavirus cell entry–related genes in mouse OB. (A) UMAP visualization of OB scSeq highlighting the main cell classes and subtypes from two 
integrated scSeq datasets (see Materials and Methods). VIP, vasoactive intestinal peptide–expressing neurons; ETCs, external tufted cells; OPCs, oligodendrocyte precursor 
cells; IPCs, intermediate precursor cells. Cluster information is summarized in figs. S7 and S8. (B) UMAP representation of the vascular cell cluster showing expression of 
CoV-2 entry–related genes (Ace2 and Tmprss2) and Kcnj8, a pericyte marker. Color scale depicts log-normalized UMI counts. (C) Normalized gene expression of corona virus 
cell entry–related genes and cell class markers in mouse OB. Color scale shows scaled mean expression level per cell type, normalized by their maximum expression across 
cell types. Ace2 is specifically expressed in vascular cells. (D) Percentage of cells expressing Ace2. “Other vascular” denotes all vascular cells excluding pericytes. Ace2 ex-
pression was only detected in vascular cell types. (E) Log2-normalized expression [log2(TPM + 1)] of coronavirus entry genes and dopaminergic neuron markers 
in manually sorted and deeply sequenced single OB dopaminergic neurons. (F) ACE2 immunostaining of the mouse main OB. Left: Section of OB containing the 
glomerular layer (with example glomeruli circled), mitral cell layer (MCL), and granule cell layer (GCL). ACE2 protein is present in vascular mural cells but not in OB 
neurons or OSN axons. Boxes (i) and (ii) indicate the locations of enlarged images. Scale bar, 100 m. (i) Middle: Enlarged image of glomerular layer. ACE2 protein staining 
was restricted to vascular cells. Scale bar, 50 m. (ii) Right: Enlarged image of MCL (dashed line) and GCL showing the lack of ACE2. Scale bar, 50 m. (G) An OB section 
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the mouse suggests that ACE2 protein is (nearly) ubiquitously 
expressed in SUS cells in the dorsal OE, despite sparse detection of 
Ace2 transcripts using scSeq. Similarly, nearly all vascular pericytes 
also expressed ACE2 protein, although only a fraction of OB peri-
cytes were positive for Ace2 transcripts when assessed using scSeq. 
Although Ace2 transcripts were more rarely detected than protein, 
there was a clear concordance at the cell-type level: Expression of 
Ace2 mRNA in a particular cell type accurately predicted the pres-
ence of ACE2 protein, while Ace2 transcript–negative cell types 
(including OSNs) did not express ACE2 protein. These observa-
tions are consistent with recent findings in the RE, suggesting that 
scSeq substantially underestimates the fraction of a given cell type 
that expresses the Ace2 transcript, but that “new” Ace2-expressing 
cell types are not found with more sensitive forms of analysis (40). 
If our findings in the mouse OE translate to the human (a reasonable 
possibility given the precise match in olfactory cell types that express 
CoV-2 cell entry genes between the two species), then ACE2 pro-
tein is likely to be expressed in a significant subset of human SUS 
cells. Thus, there may be many olfactory support cells available for 
CoV-2 infection in the human epithelium, which in turn could 
nucleate a pathophysiological process that culminates in anosmia. 
However, it remains possible that damage to the OE could be caused by 
more limited cell infection. For example, infection of subsets of SUS 
cells by the coronavirus SDAV (sialodacryoadenitis virus) in rats 
ultimately leads to disruption of the global architecture of the OE, 
suggesting that focal coronavirus infection may be sufficient to cause 
diffuse epithelial damage (56).
We observe that activated HBCs, which are recruited after injury, 
express Ace2 at higher levels than those apparent in resting stem cells. 
The natural history of CoV-2–induced anosmia is only now being 
defined; while recovery of smell on time scales of weeks in many 
patients has been reported, it remains unclear whether, in a subset 
of patients, smell disturbances will be long-lasting or permanent 
(8–12, 57). While on its own it is unlikely that infection of stem cells 
would cause acute smell deficits, the capacity of CoV-2 to infect stem 
cells may play an important role in those cases in which COVID-19–
associated anosmia is persistent, a context in which infection of stem 
cells could inhibit OE regeneration and repair over time.
Two anosmic patients with COVID-19 have presented with 
functional magnetic resonance imaging–identified hyperintensity 
in both OBs that reverted to normal after resolution of the anosmia 
(58, 59), consistent with central involvement in at least some cases. 
Many viruses, including coronaviruses, have been shown to propagate 
from the nasal epithelium past the cribriform plate to infect the OB; 
this form of central infection has been suggested to mediate olfactory 
deficits, even in the absence of lasting OE damage (60–65). The 
rodent coronavirus MHV (mouse hepatitis virus) passes from the 
nose to the bulb, although rodent OSNs do not express Ceacam1, 
the main MHV receptor (figs. S4C, S5E, and S6A) (61, 66), suggesting 
that CoVs in the nasal mucosa can reach the brain through mecha-
nisms independent of axonal transport by sensory nerves; OB dopa-
minergic juxtaglomerular cells express Ceacam1 (Fig. 7E), which 
likely supports the ability of MHV to target the bulb and change odor 
perception. Although SARS-CoV has been shown to infect the OB 
in a transgenic mouse model that ectopically expresses human ACE2 
(65), it is unclear to what extent similar results will be observed for 
CoV-2 in this mouse and in recently developed mouse models ex-
pressing human ACE2 that better recapitulate native expression 
patterns (67–69). One speculative possibility is that local seeding of 
the OE with CoV-2–infected cells can result in OSN-independent 
transfer of virions from the nose to the bulb, perhaps via the vascular 
supply shared between the OB and the OSN axons that comprise 
CN I. Although CN I was not directly queried in our datasets, it is 
reasonable to infer that vascular pericytes in CN I also express ACE2, 
which suggests a possible route of entry for CoV-2 from the nose 
into the brain. Given the absence of ACE2 in mouse OB neurons—
and the near-ubiquity of ACE2 expression in OB pericytes—we 
speculate that any central olfactory dysfunction in COVID-19 is the 
secondary consequence of inflammation arising locally from peri-
cytes, or in response to diffusable factors arising from more distant 
sources (51).
Multiple immunostaining studies reveal that ACE2 protein in the 
human brain is predominantly or exclusively expressed in vascula-
ture (and specifically expressed within pericytes) (52, 53, 70), and 
many neurological symptoms associated with CoV-2 infection such 
as stroke or altered consciousness are consistent with an underlying 
vasculopathy (71–76). In addition, human cerebrospinal fluid (CSF) 
samples have failed thus far to reveal CoV-2 RNA (73, 77), and 
autopsies from human patients have found that the brain contains 
the lowest levels of CoV-2 across organs sampled (78). On the other 
hand, multiple other studies have suggested that ACE2 may be ex-
pressed in human neurons and glia (79–82). In addition, two recent 
studies in mouse models expressing human ACE2 have found CoV-2 
in the brain after intranasal inoculation (67, 68), although neither 
specifically queried the OB; this work stands in contrast to results in 
a nonhuman primate model of COVID-19, in which nasal infection 
did not lead to the presence of identifiable CoV-2 antigens in the 
brain (83). Further work will be required to resolve these inconsistencies 
and to definitively characterize the distribution of ACE2 protein 
and ultimately CoV-2–infected cells in the human OB and brain.
We note several caveats that temper our conclusions. Although 
current data suggest that ACE2 is the most likely receptor for CoV-2 
in vivo, it is possible (although it has not yet been demonstrated) 
that other molecules such as BSG (basigin) may enable CoV-2 entry 
independently of ACE2 (figs. S1E, S4C, S5E, and S6A) (84, 85). In 
addition, it has recently been reported that low-level expression of 
ACE2 can support CoV-2 cell entry (86); it is possible, therefore, 
that ACE2 expression beneath the level of detection in our assays 
may yet enable CoV-2 infection of apparently ACE2-negative cell 
types. We also propose that damage to the olfactory system is due 
to either primary infection or secondary inflammation; it is possible 
(although it has not yet been demonstrated) that cells infected with 
CoV-2 can form syncytia with cells that do not express ACE2. Such 
a mechanism could damage neurons adjacent to infected cells. Last, 
it has recently been reported that inflammation can induce expres-
sion of ACE2 in human cells (87, 88). It is therefore possible that our 
survey of ACE2 expression, and other recent reports demonstrating 
expression of ACE2 in OE support and stem cells but not neurons 
(81, 89, 90), might underrepresent the cell types that express ACE2 
under conditions of CoV-2 infection.
Any reasonable pathophysiological mechanism for COVID-19–
associated anosmia must account for the high penetrance of smell 
disorders relative to endemic viruses (12, 91, 92), the apparent 
suddenness of smell loss that can precede the development of other 
symptoms (11, 13), and the transient nature of dysfunction in many 
patients (11, 17, 18); definitive identification of the disease mechanisms 
underlying COVID-19–mediated anosmia will require additional 
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expressing molecules known to be involved in CoV-2 entry illumi-
nates a path forward for future studies.
MATERIALS AND METHODS
Human nasal scSeq dataset
Human scSeq data from Durante et al. (38) were downloaded from 
the Gene Expression Omnibus (GEO) at accession GSE139522. 10× 
Genomics mtx files were filtered to remove any cells with fewer 
than 500 total counts. Additional preprocessing, including normal-
izing total counts to the median total counts for each cell and filter-
ing for highly variable genes, was performed using the SPRING gene 
filtering function “filter_genes” with parameters (90, 3, 10). The result-
ing data were visualized in SPRING and partitioned using Louvain 
clustering on the SPRING k-nearest neighbor graph. Four clusters were 
removed for quality control, including two with low total counts 
(likely background) and two with high mitochondrial counts (likely 
stressed or dying cells). Putative doublets were also identified us-
ing Scrublet and removed (7% of cells). The remaining cells were 
projected to 40 dimensions using principal components analysis 
(PCA). PCA batch correction was performed using patient 4 as a 
reference, as previously described (93). The filtered data were then 
repartitioned using Louvain clustering on the SPRING graph, and 
each cluster was annotated using known marker genes, as described in 
(38). For example, immature OSNs (iOSNs) and mOSNs were iden-
tified via their expression of GNG8 and GNG13, respectively. HBCs 
were identified via the expression of KRT5 and TP63, and olfactory 
HBCs were distinguished from respiratory HBCs via the expres-
sion of CXCL14 and MEG3. Identification of SUS cells (CYP2A13 
and CYP2J2), BG (SOX9 and GPX3), and MV ionocyte–like cells 
(ASCL3, CFTR, and FOXI1) was also performed using known 
marker genes. For visualization, the top 40 principal components 
(PCs) were reduced to two dimensions using UMAP with parameters 
(n_neighbors = 15, min_dist = 0.4).
The filtered human scSeq dataset contained 33,358 cells. Each 
of the samples contained cells from both the OE and RE, although the 
frequency of OSNs and respiratory cells varied across patients, as 
previously described (38). A total of 295 cells expressed ACE2, and 
4953 cells expressed TMPRSS2. Of the 865 identified OSNs, includ-
ing both immature and mature cells, none of the cells express ACE2, 
and only 2 (0.23%) expressed TMPRSS2. In contrast, ACE2 was re-
liably detected in at least 2%, and TMPRSS2 was expressed in close 
to 50% of multiple respiratory epithelial subtypes. The expression 
of both known cell-type markers and known CoV-related genes 
was also examined across respiratory and olfactory epithelial cell 
types. For these gene sets, the mean expression in each cell type was 
calculated and normalized by the maximum across cell types.
Mapping scSeq datasets to each other
Data from Deprez et al. (41) were downloaded from the Human Cell 
Atlas website [www.genomique.eu/cellbrowser/HCA/; “Single-cell 
atlas of the airway epithelium (Grch38 human genome)”]. A subset 
of these data was combined with a subset of the Durante et al. data 
for mapping between cell types. For the Deprez et al. data, the subset 
consisted of samples from the nasal RE that belonged to a cell type 
with >20 cells, including basal, cycling basal, suprabasal, secretory, 
mucous multiciliated cells, multiciliated, SMG (submucosal gland) gob-
let, and ionocyte. We observed two distinct subpopulations of basal 
cells, with one of the two populations distinguished by expression 
of CXCL14. The cells in this population were manually identified 
using SPRING and defined for downstream analysis as a separate 
cell-type annotation called “basal (CXCL14+).” For the Durante 
data, the subset consisted of cells from cell types that had some 
putative similarity to cells in the Deprez dataset, including olfactory 
HBC, cycling respiratory HBC, respiratory HBC, early respiratory 
secretory cells, respiratory secretory cells, SUS cells, BG, and olfactory 
MV cells.
To establish a cell-type mapping:
1) Data from Durante et al. (38) and Deprez et al. (41) were 
combined, and gene expression values were linearly scaled so that 
all cells across datasets had the same total counts. PCA was then 
performed using highly variable genes (n = 1477 genes) and PCA 
batch correction (93) with the Durante et al. data as a reference set.
2) Mapping was then performed bidirectionally between the two 
datasets. Each cell from “dataset 1” “voted” for the five most similar 
cells in “dataset 2,” using distance in PCA space as the measure of 
similarity. A table T counting votes across cell types was then com-
puted, where for cell type i in dataset 1 and cell type j in dataset 2
  T ij = {number of votes cast from cells of type i to cells of type j} 
Thus, if dataset 1 has N cells, then T would count 5 × N votes 
(∑Tij = 5N).
3) The table of votes T was z-scored against a null distribution, 
generated by repeating the procedure above 1000 times with shuf-
fled cell-type labels.
The resulting z scores were similar between the two possible 
mapping directions (Durante → Deprez versus Deprez → Durante; 
R = 0.87 Pearson correlation of mapping z scores). The mapping z 
scores were also highly robust upon varying the number of votes 
cast per cell (R > 0.98 correlation of mapping z scores upon changing 
the vote numbers to 1 or 50 as opposed to 5). Only cell-type 
correspondences with a high z score in both mapping directions 
(z score > 25) were used for downstream analysis.
To establish a common scale of gene expression between datasets, 
we restricted our analyses to cell-type correspondences that were 
supported both by bioinformatic mapping and shared a nominal 
cell-type designation based on marker genes. These included basal/
suprabasal cells = “respiratory HBCs” from Durante et al. and “basal” 
and “suprabasal” cells from Deprez et al.; secretory cells = “early 
respiratory secretory cells” and “respiratory secretory cells” from 
Durante et al. and “secretory” cells from Deprez et al.; and multi-
ciliated cells = “respiratory ciliated cells” from Durante et al. and 
“multiciliated” cells from Deprez et al.
We next sought a transformation of the Durante et al. data so 
that it would agree with the Deprez et al. data within the corre-
sponding cell types identified above. To account for differing 
normalization strategies applied to each dataset before download 
(log normalization and rescaling with cell-specific factors for 
Deprez et al. but not for Durante et al.), we used the following ansatz 
for the transformation, where the pseudo-count p is a global latent 
parameter and the rescaling factors fi are fit to each gene separately. 
In the equation below, T denotes the transformation, and eij represents 
a gene expression value for cell i and gene j in the Durante data
  T( e ij ) = (log( e ij + p) − log(p))/ f j 
The parameter p was fit by maximizing the correlation of average 
gene expression across all genes between each of the cell-type correspon-
dences listed above. The rescaling factors fi were then fitted separately 
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between the Deprez et al. data and the log-transformed Durante et al. 
data, again across the cell-type correspondences listed above.
Mouse bulk RNA-seq datasets
Normalized gene expression tables were obtained from previous 
published datasets (Table 1) (43, 46–48). For the mouse datasets, 
the means of the replicates from WOM or OSN were used to calcu-
late log2 fold changes. For the mouse data from Saraiva et al. (43, 46) 
and the primate datasets, the normalized counts of the genes of 
interest from individual replicates were plotted.
Mouse WOM Drop-seq experiments
Tissue dissection and single-cell dissociation for nasal epithelium
A new dataset of WOM scSeq was generated from adult male mice 
(8 to 12 weeks old). All mouse husbandry and experiments were 
performed following institutional and federal guidelines and approved 
by Harvard Medical School’s Institutional Animal Care and Use 
Committee (IACUC). Briefly, dissected main OE was cleaned up in 
750 l of EBSS (Earle’s balanced salt solution; Worthington), and 
epithelium tissues were isolated in 750 l of papain (20 U/ml in EBSS) 
and 50 l of deoxyribonuclease I (DNase I) (2000 U/ml). Tissue pieces 
were transferred to a 5-ml round-bottom tube (BD), and 1.75 ml of 
papain and 450 l of DNase I were added. After 1- to 1.5-hour incu-
bation with rocking at 37°C, the suspension was triturated with a 5-ml 
pipette 15 times and passed through a 40-m cell strainer (BD), and the 
strainer was washed with 1 ml of Dulbecco’s modified Eagle’s medium 
(DMEM) + 10% fetal bovine serum (FBS) (Invitrogen). The cell suspen-
sion was centrifuged at 300g for 5 min. Cells were resuspended with 
4 ml of DMEM + 10% FBS and centrifuged at 300g for 5 min. Cells were 
suspended with phosphate-buffered saline (PBS) + 0.01% bovine serum 
albumin (BSA), and concentration was measured by a hemocytometer.
Drop-seq experiments
Drop-seq experiments were performed as previously described (94). 
Microfluidics devices were obtained from FlowJEM, and barcode 
beads were obtained from ChemGenes. Eight 15-min Drop-seq 
runs were collected in total, which were obtained from five mice.
Sequencing of Drop-seq samples
Eight replicates of Drop-seq samples were sequenced across five 
runs on an Illumina NextSeq 500 platform. Paired-end reads from 
the fastq files were trimmed, aligned, and tagged via the Drop-seq 
tools (v1.13) pipeline, using STAR (v2.5.4a) with genomic indices 
from Ensembl Release 93. The digital gene expression matrix was 
generated for 4000 cells for 0126_2; 5000 cells for 0105, 0126_1, 
051916_DS11, 051916_DS12, and 051916_DS22; 5500 cells for 
051916_DS21; and 9500 cells for 0106.
Preprocessing of Drop-seq samples
Processing of the WOM Drop-seq samples was performed in Seurat 
(v2.3.1). Cells with less than 500 UMIs or more than 15,000 unique 
molecular identifiers (UMIs), or higher than 5% mitochondrial 
genes, were removed. Potential doublets were removed using 
Scrublet. Cells were initially preprocessed using the Seurat pipeline. 
Variable genes “FindVariableGenes” (y.cutoff = 0.6) were scaled 
[regressing out effects due to number of UMIs (nUMI), the per-
centage of mitochondrial genes, and replicate ids], and the data 
were clustered using 50 PCs with the Louvain algorithm (resolu-
tion = 0.8). In a fraction of SUS cells, we observed coexpression of 
markers for SUS cells and other cell types (e.g., OSNs). Reclustering 
of SUS cells alone separated these presumed doublets from the rest 
of the SUS cells, and the presumed doublets were removed for the 
analyses described below.
Processing of Drop-seq samples
The filtered cells from the preprocessing steps were reanalyzed in 
Python using Scanpy and SPRING. In brief, the raw gene counts in 
each cell were total counts normalized, and variable genes were 
identified using the SPRING gene filtering function “filter_genes” 
with parameters (85, 3, 3); mitochondrial and olfactory receptor genes 
were excluded from the variable gene lists. The resulting 2083 variable 
genes were Z-scored, and the dimensionality of the data was reduced 
to 35 via PCA. The k-nearest neighbor graph (n_neighbors = 15) of 
these 35 PCs was clustered using the Leiden algorithm (resolution = 1.2) 
and was reduced to two dimensions for visualization via the UMAP 
method (min_dist = 0.42). Clusters were manually annotated on the 
basis of known marker genes, and those sharing markers (e.g. OSNs) 
were merged.
The mouse WOM Drop-seq dataset contained 29,585 cells that 
passed the above filtering. Each of the 16 clusters identified contained 
cells from all eight replicates in roughly equal proportions. Of the 
17,666 mOSNs and the 4674 iOSNs, none of the cells express Ace2. 
Table 1. Sample information for the bulk RNA-seq data analyzed in this study. Three different mouse bulk RNA-seq datasets were used, each with 
replicates from WOM or purified OSNs. An additional dataset contained bulk RNA-seq data from humans and nonhuman primates. n.s., not specified; OMP, 
olfactory marker protein; IRES, internal ribosomal entry site; GFP, green fluorescent protein; WT, wild type; NA, not applicable. 
Source Species Reps Samples per rep Sex (M/F) Age Strain Geno
Saraiva et al. (46)
WOM Mouse 3 1 2/1 P21 OMP-IRES-GFP GFP/+
OSN Mouse 3 14–16 Mixed P25 OMP-IRES-GFP GFP/+
Kanageswaran 
et al. (47)
WOM Mouse 4 3 F 4 weeks C57BL/6J WT
OSN Mouse 2 6–8 Mixed Adult OMP-IRES-GFP GFP/+ or GFP/GFP
Colquitt et al. 
(48)
WOM Mouse 2 n.s. n.s. 3 weeks Dnmt3a WT
OSN Mouse 2 n.s. n.s. 3 weeks Dnmt3a WT
Saraiva et al. (43)
WOM Human 3 1 3/0 n.s. NA
WOM Macaque 3 1 n.s. ~4.5 years NA
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In contrast, in the olfactory epithelial cells, Ace2 expression was ob-
served in the BG, olfactory HBCs, and dorsal SUS cells.
Immunohistochemistry and in situ hybridization of  
mouse and human tissue
Mouse OE tissue processing
Mice were euthanized with a lethal dose of xylazine, and nasal epi-
thelium with attached OBs was dissected and fixed in 4% para-
formaldehyde (Electron Microscope Sciences, 19202) in PBS overnight 
at 4°C or for 2 hours at room temperature. Tissues were washed three 
times in PBS (5 min each) and incubated in 0.45 M EDTA in PBS 
overnight at 4°C. The following day, tissues were rinsed by PBS, in-
cubated in 30% sucrose in PBS for at least 30 min, transferred to 
Tissue Freezing Medium (VWR, 15146-025) for at least 45 min, frozen 
on crushed dry ice, and stored at −80°C until sectioning. Tissue sec-
tions (20 m thick for the OB and 12 m thick for nasal epithelium) 
were collected on Superfrost Plus glass slides (VWR, 48311703) and 
stored at −80°C until immunostaining. For methimazole-treated 
samples, adult C57BL/6J mice (6 to 12 weeks old; JAX stock no. 000664) 
were given intraperitoneal injections of 50 g of methimazole per gram 
of body weight (Sigma-Aldrich, M8506) and euthanized at 24-, 48-, 
and 96-hour time points.
Immunostaining for mouse tissue
Sections were permeabilized with 0.1% Triton X-100 in PBS for 
20 min and then rinsed three times in PBS. Sections were then incu-
bated for 45 to 60 min in blocking solution that consisted of PBS 
containing 3% BSA (Jackson ImmunoResearch, 001-000-162) and 
3% Donkey Serum (Jackson ImmunoResearch, 017-000-121) at room 
temperature, followed by overnight incubation at 4°C with primary 
antibodies diluted in the same blocking solution. Primary antibodies 
used are as follows: goat anti-ACE2 (Thermo Fisher Scientific, PA5-
47488; 1:40), mouse anti-TUBB4 (Sigma-Aldrich, T7941; 1:4000), 
rabbit anti-KRT5 (Abcam, ab52635; 1:200), goat anti-NQO1 (Abcam, 
ab2346; 1:200), mouse antiacetylated tubulin (Abcam, ab24610; 1:500), 
rabbit anti-CNGA2 (Abcam, ab79261; 1:100), and rat anti-CD140b/
PDGFRB (Thermo Fisher Scientific, 14-1402-82; 1:100).
On the following day, sections were rinsed once and washed 
three times for 5 to 10 min in PBS and then incubated for 45 min 
with secondary antibodies diluted in blocking solution at 1:300 ratios 
and/or Alexa Fluor 555–conjugated phalloidin (1:400). Secondary 
antibodies used were as follows: donkey anti-goat immunoglobulin 
G (IgG) Alexa Fluor 488 (Jackson ImmunoResearch, 705-546-147), 
donkey anti-goat IgG Alexa 555, (Invitrogen, A21432), donkey 
anti-rabbit IgG Alexa 555 (Invitrogen, A31572), donkey anti-rabbit 
IgG Alexa 647 (Jackson ImmunoResearch, 711-605-152), donkey 
anti-mouse IgG Alexa 555 (Invitrogen, A31570), donkey anti- mouse 
IgG Alexa 647 (Invitrogen, A31571), and donkey anti-rat IgG Alexa 
488 (Invitrogen, A21208).
After secondary antibody incubation, sections were washed twice 
for 5 to 10 min in PBS, incubated with 300 nM 4′,6-diamidino- 2-
phenylindole (DAPI) in PBS for 10 min, and then rinsed with 
PBS. Slides were mounted with glass coverslips using VECTASHIELD 
Mounting Medium (Vector Laboratories, H-1000) or ProLong 
Diamond Antifade Mountant (Invitrogen, P36961).
For costaining of ACE2 and NQO1, slides were first stained with 
ACE2 primary antibody and donkey anti-goat IgG Alexa 488 
secondary. After three washes of secondary antibody, tissues were 
incubated with unconjugated donkey anti-goat IgG Fab fragments 
(Jackson ImmunoResearch, 705-007-003) at 30 g/ml diluted in 
blocking solution for 1 hour at room temperature. Tissues were 
washed twice with PBS, once in blocking solution, and incubated in 
blocking solution for 30 to 40 min at room temperature, followed 
by a second round of staining with the NQO1 primary antibody and 
donkey anti-goat IgG Alexa 555 secondary antibody.
Confocal images were acquired using a Leica SPE microscope 
(Harvard Medical School Neurobiology Imaging Facility) with 405-, 
488-, 561-, and 635-nm laser lines. Multislice Z-stack images were 
acquired, and their maximal intensity projections are shown. For 
Fig. 5A, tiled images were acquired and stitched by the Leica LAS X 
software. Images were processed using Fiji ImageJ software (95), and 
noisy images were median-smoothed using the Remove Outliers 
function built into Fiji.
Fluorescence in situ hybridization for mouse tissue
Sult1c1 RNA was detected by fluorescent RNAscope assay (Advanced 
Cell Diagnostics, kit 320851) using probe 539921-C2, following the 
manufacturer’s protocol (RNAscope Fluorescent Multiplex Kit User 
Manual, 320293-UM Date 03142017) for paraformaldehyde-fixed 
tissue. Before initiating the hybridization protocol, the tissue was 
pretreated with two successive incubations (first 30 min and then 
15 min long) in RNAscope Protease III (Advanced Cell Diagnostics, 
322337) at 40°C and then washed in distilled water. At the end of 
the protocol, the tissue was washed in PBS and subjected to the 
2-day immunostaining protocol described above.
Immunostaining of human nasal tissue
Human olfactory mucosa biopsies were obtained via the Institu-
tional Review Board–approved protocol at Duke University School 
of Medicine, from nasal septum or superior turbinate during endo-
scopic sinus surgery. Tissue was fixed with 4% paraformaldehyde 
and cryosectioned at 10 m, and sections were processed for immuno-
staining, as previously described (38).
Sections from a 28-year-old female nasal septum biopsy were 
stained for ACE2 (Fig. 2E) using the same goat anti-ACE2 (Thermo 
Fisher Scientific, PA5-47488; 1:40) and the protocol described above 
for mouse tissue. The human sections were costained with rabbit 
anti-keratin 5 (Abcam, ab24647; AB_448212, 1:1000) and were detected 
with Alexa Fluor 488 donkey anti-goat (Jackson ImmunoResearch, 
705-545-147) and Alexa Fluor 594 donkey anti-rabbit (Jackson 
ImmunoResearch, 711-585-152) secondary antibodies (1:300).
As further validation of ACE2 expression and to confirm the 
lack of ACE2 expression in human OSNs (fig. S2), sections were 
stained with a rabbit anti-ACE2 (Abcam, ab15348; RRID:AB_301861, 
used at 1:100) antibody immunogenized against human ACE2 and 
a mouse Tuj1 antibody against neuron-specific tubulin (BioLegend, 
801201; RRID:AB_2313773). Anti-ACE2 was raised against a C-terminal 
synthetic peptide for human ACE2 and was validated by the manu-
facturer to not cross-react with ACE1 for immunohistochemical 
labeling of ACE2 in fruit bat nasal tissue and in human lower airway. 
Recombinant human ACE2 abolished labeling with this antibody in 
a previous study in human tissue, further demonstrating its speci-
ficity (53). The Tuj1 antibody was validated, as previously described 
(38). Biotinylated secondary antibodies (Vector Laboratories), 
avidin-biotinylated horseradish peroxidase kit (Vector Laboratories), 
and fluorescein tyramide signal amplification (PerkinElmer) were 
applied per the manufacturer’s instructions. For dual staining, Tuj1 
was visualized using Alexa Fluor 594 goat anti-mouse (Jackson 
ImmunoResearch, 115-585-146; RRID: AB_2338881).
Human sections were counterstained with DAPI, and coverslips 
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a Leica DMi8 microscope system. Images were processed using Fiji 
ImageJ software (National Institutes of Health). Scale bars were applied 
directly from the Leica acquisition software metadata in ImageJ 
tools. Unsharp mask was applied in ImageJ, and brightness/contrast 
was adjusted globally.
WOM and HBC lineage–tracing mouse 10× scSeq experiments
Mice
Two-month-old and 18-month-old wild-type C57BL/6J mice were 
obtained from the National Institute on Aging Aged Rodent Colony 
and used for the WOM experiments; each experimental condition 
consisted of one male and one female mouse to aid doublet detection. 
Mice containing the transgenic Krt5-CreER(T2) driver (96) and 
Rosa26–yellow fluorescent protein (YFP) reporter allele (97) were 
used for the HBC lineage–tracing dataset. All mice were assumed to 
be of normal immune status. Animals were maintained and treated 
according to federal guidelines under IACUC oversight at the 
University of California, Berkeley.
Single-cell RNA sequencing
The OE was surgically removed, and the dorsal, sensory portion was 
dissected and dissociated, as previously described (36). For WOM 
experiments, dissociated cells were subjected to fluorescence-activated 
cell sorting (FACS) using propidium iodide to identify and select 
against dead or dying cells; 100,000 cells per sample were collected 
in 10% FBS. For the HBC lineage–tracing experiments, Krt5-CreER; 
Rosa26YFP/YFP mice were injected once with tamoxifen (0.25 mg 
of tamoxifen per gram of body weight) at postnatal day 21 (P21) to 
P23 of age and euthanized at 24 hours, 48 hours, 96 hours, 7 days, 
and 14 days after injury, as previously described (36, 98). For each 
experimental time point, YFP+ cells were isolated by FACS based on 
YFP expression and negative for propidium iodide, a vital dye.
Cells isolated by FACS were subjected to scSeq. Three replicates 
(defined here as a FACS collection run) per age were analyzed for 
the WOM experiment; at least two biological replicates were collected 
for each experimental condition for the HBC lineage–tracing experi-
ment. Single-cell complementary DNA (cDNA) libraries from the 
isolated cells were prepared using the Chromium Single Cell 3′ 
System according to the manufacturer’s instructions. The WOM 
preparation used v3 chemistry with the following modification: The 
cell suspension was directly added to the reverse transcription master 
mix, along with the appropriate volume of water to achieve the 
approximate cell capture target. The HBC lineage–tracing experi-
ments were performed using v2 chemistry. The 0.04% (w/v) BSA 
washing step was omitted to minimize cell loss. Completed libraries 
were sequenced on Illumina HiSeq 4000 to produce paired-end 
100- nucleotide reads.
Sequence data were processed with the 10× Genomics Cell 
Ranger pipeline (2.0.0 for v2 chemistry), resulting in the initial 
starting number before filtering of 60,408 WOM cells and 25,469 
HBC lineage–traced cells. The scone R/Bioconductor package (99) 
was used to filter out lowly expressed genes (fewer than two UMIs 
in fewer than five cells) and low-quality libraries (using the metric_
sample_filter function with arguments hard_nreads = 2000, zcut = 4).
Preliminary filtering
Cells with coexpression of male (Ddx3y, Eif2s3y, Kdm5d, and Uty) 
and female marker genes (Xist) were removed as potential doublets 
from the WOM dataset. For both datasets, doublet cell detection 
was performed per sample using DoubletFinder (100) and Scrublet 
(101). Genes with at least three UMIs in at least five cells were used 
for downstream clustering and cell-type identification. For the HBC 
lineage–tracing dataset, the Bioconductor package scone was used 
to pick the top normalization (“none,fq,ruv_k = 1,no_bio,batch”), 
corresponding to full quantile normalization, batch correction, and 
removing one factor of unwanted variation using the RUVSeq 
Bioconductor package (102). A range of cluster labels were created 
by clustering using the partitioning around medoids algorithm and 
hierarchical clustering in the clusterExperiment Bioconductor package 
(103), with parameters k0s = (10, 13, 16, 19, 22, 25) and alpha = 
(NA, 0.1, 0.2, 0.3). Clusters that did not show differential expression 
were merged (using the function mergeClusters with arguments 
mergeMethod = “adjP,” cutoff = 0.01, and DEMethod = “limma” 
for the lineage-traced dataset). Initial clustering identified one macro-
phage (Msr1+) cluster consisting of 252 cells; upon its removal and 
restarting from the normalization step, a subsequent set of 15 clus-
ters was obtained. These clusters were used to filter out 1515 cells 
for which no stable clustering could be found (i.e., “unassigned” 
cells) and four clusters respectively consisting of 31, 29 and 23 and 
305 cells. Doublets were identified using DoubletFinder, and 271 
putative doublets were removed. Inspection of the data in a three- 
dimensional UMAP embedding identified two groups of cells whose 
experimentally sampled time point did not match their position along 
the HBC differentiation trajectory, and these additional 219 cells were 
also removed from subsequent analyses.
Analysis of CoV-related genes in WOM and HBC lineage  
10× datasets
Analysis of WOM scSeq data was performed in Python using the 
open-source Scanpy software starting from the raw UMI count matrix 
of the 40,179 cells passing the initial filtering and quality control 
criteria described above. UMIs were total count–normalized and 
scaled by 10,000 [TPT (tag per ten thousands)] and then log-normalized. 
For each gene, the residuals from linear regression models using the 
total number of UMIs per cell as predictors were then scaled via Z 
scoring. PCA was then performed on a set of highly variable genes 
(excluding olfactory receptor genes) calculated using the “highly_
variable_genes” function with the following parameters: min_
mean = 0.01, max_mean = 10, and min_disp = 0.5. A batch-corrected 
neighborhood graph was constructed by the “bbknn” function with 
42 PCs with the following parameters: local_connectivity = 1.5 and 
embedding two dimensions using the UMAP function with default 
parameters (min_dist = 0.5). Cells were clustered using the neighborhood 
graph via the Leiden algorithm (resolution = 1.2). Identified clusters 
were manually merged and annotated on the basis of known marker 
gene expression. We removed 281 cells containing mixtures of marker 
genes with no clear gene expression signature. The identified cell 
types and the number of each of the remaining 39,898 cells detected 
were as follows: 28,769 mOSNs, 2607 iOSNs, 859 immediate neural 
precursors (INPs), 623 GBCs, HBCs (1083 olfactory and 626 respi-
ratory), 480 SUS cells, 331 BG, MV cells (563 brush-like and 
1530 ionocyte-like), 92 olfactory ensheathing cells (OECs), 76 respi-
ratory secretory cells, 227 respiratory unspecified cells, 172 atypical 
OSNs, 1757 various immune cells, and 103 red blood cells. TPT gene 
expression levels were visualized in two-dimensional UMAP plots.
The filtered HBC lineage dataset containing 21,722 cells was an-
alyzing in Python and processed for visualization using pipelines in 
SPRING and Scanpy (104, 105). In brief, total counts were normal-
ized to the median total counts for each cell, and highly variable 
genes were selected using the SPRING gene filtering function (“filter_
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was reduced to 20 using PCA and visualized in two dimensions using 
the UMAP method with parameters (n_neighbors = 20, min_dist = 0.5). 
Clustering was performed using the Leiden algorithm (resolution = 1.45), 
and clusters were merged manually using known marker genes. The 
identified cell types and number of each type were 929 mOSNs, 
2073 iOSNs, 786 INPs, 755 GBCs, HBCs (7782 olfactory, 5418 
regenerating, and 964 respiratory), 2666 SUS cells, and 176 ionocyte- 
like MV cells.
Expression of candidate CoV-2–related genes was defined if at 
least one transcript (UMI) was detected in that cell, and the percentage 
of cells expressing candidate genes was calculated for each cell type. 
In the WOM dataset, Ace2 was only detected in 2 of 28,769 mOSNs 
(0.007%), and in the HBC lineage dataset, Ace2 was not detected in 
any OSNs. Furthermore, Ace2 was not detected in immature sensory 
neurons (GBCs, INPs, or iOSNs) in either dataset.
Mouse HBC lineage Smart-seq2 dataset
scSeq data from HBC-derived cells from Fletcher et  al. (36) and 
Gadye et al. (98), labeled via Krt5-CreER driver mice, were down-
loaded from GEO at accession GSE99251 using the file “GSE95601_
oeHBCdiff_Cufflinks_eSet_counts_table.txt.gz”. Processing was 
performed as described above, including total count normalization 
and filtering for highly variable genes using the SPRING gene filter-
ing function “filter_genes” with parameters (75, 20, 10). The result-
ing data were visualized in SPRING, and a subset of cells were 
removed for quality control, including a cluster of cells with low 
total counts and another with predominantly reads from ERCC 
(External RNA Controls Consortium) spike-in controls. Putative 
doublets were also identified using Scrublet and removed (6% of 
cells) (101). The resulting data were visualized in SPRING and parti-
tioned using Louvain clustering on the SPRING k-nearest neighbor 
graph using the top 40 PCs. Cell-type annotation was performed 
manually using the same set of marker genes listed above. Three 
clusters were removed for quality control, including one with low 
total counts, one with predominantly reads from ERCC spike-in 
controls (likely background), and one with high mitochondrial counts 
(likely stressed cells). For visualization and clustering, the remaining 
cells were projected to 15 dimensions using PCA and visualized 
with UMAP with parameters (n_neighbors = 15, min_dist = 0.4, 
alpha = 0.5, maxiter = 500). Clustering was performed using the 
Leiden algorithm (resolution = 0.4), and cell types were manually 
annotated using known marker genes.
The filtered dataset of mouse HBC-derived cells contained 1450 cells. 
The percentage of cells expressing each marker gene was calculated 
as described above. Of the 51 OSNs identified, none of them expressed 
Ace2, and only 1 of 194 INPs and iOSNs expressed Ace2. In contrast, 
Ace2 and Tmprss2 were both detected in HBCs and SUS cells.
Juvenile and adult mouse whole OB scSeq dataset
Juvenile mouse data
scSeq data from whole mouse OB (50) were downloaded from 
mousebrain.org/loomfiles_level_L1.html in loom format (l1 olfactory.
loom) and converted to a Seurat object. Samples were obtained 
from juvenile mice (age P26 to P29). This dataset comprises 20,514 
cells that passed cell quality filters, excluding 122 cells identified as 
potential doublets.
Tissue dissection and single-cell dissociation
A new dataset of whole OB scSeq was generated from adult male mice 
(8 to 12 weeks old). All mouse husbandry and experiments were 
performed following institutional and federal guidelines and approved 
by Harvard Medical School’s IACUC. Briefly, dissected OBs (including 
the accessory OB and fractions of the anterior olfactory nucleus) 
were dissociated in 750 l of dissociation medium (DM; Hanks’ balanced 
salt solution containing 10 mM Hepes, 1 mM MgCl2, and 33 mM 
d-glucose) with papain (28 U/ml) and DNase I (386 U/ml; Worthington). 
Minced tissue pieces were transferred to a 5-ml round-bottom tube 
(BD). DM was added to a final volume of 3.3 ml, and the tissue was 
mechanically triturated five times with a P1000 pipette tip. After 
1-hour incubation with rocking at 37°C, the suspension was tritu-
rated with a 10-ml pipette 10 times, and 2.3 ml was passed through 
40-m cell strainer (BD). The suspension was then mechanically 
triturated with a P1000 pipette tip 10 times, and 800 l was filtered 
on the same strainer. The cell suspension was further triturated 
with a P200 pipette tip 10 times and filtered. One milliliter of 
Quench buffer (22 ml of DM, 2.5 ml of protease inhibitor prepared 
by resuspending one vial of protease inhibitor with 32 ml of DM, and 
2000 U of DNase I) was added to the suspension and centrifuged at 
300g for 5 min. Cells were resuspended with 3 ml of Quench buffer, 
overlaid gently on top of 5 ml of protease inhibitor, and then spun 
down at 70g for 10 min. The pellet was resuspended using DM sup-
plemented with 0.04% BSA and spun down at 300g for 5 min. Cells 
were suspended in 400 l of DM with 0.04% BSA.
OB Drop-seq experiments
Drop-seq experiments were performed as previously described (94). 
Microfluidics devices were obtained from FlowJEM, and barcode 
beads were obtained from ChemGenes. Two 15-min Drop-seq runs 
were collected from a single dissociation preparation obtained from 
two mice. Two such dissociations were performed, giving four total 
replicates.
Sequencing of Drop-seq samples
Four replicates of Drop-seq samples were pooled and sequenced 
across three runs on an Illumina NextSeq 500 platform. Paired-end 
reads from the fastq files were trimmed, aligned, and tagged via the 
Drop-seq tools (1-2.0) pipeline, using STAR (2.4.2a) with genomic 
indices from Ensembl Release 82. The digital gene expression 
matrix was generated for 8000 cells per replicate.
Preprocessing of Drop-seq samples
Cells with low numbers of genes (500), low numbers of UMIs (700), 
or high numbers of UMIs (>10,000) were removed (6% of cells). 
Potential doublets were identified via Scrublet and removed (3.5% 
of cells). Overall, this new dataset comprised 27,004 cells.
Integration of whole OB scSeq datasets
Raw UMI counts from juvenile and adult whole OB samples were 
integrated in Seurat (106). Integrating the datasets ensured that 
clusters with rare cell types could be identified and that corresponding 
cell types could be accurately matched. As described below (see fig. S7), 
although some cell types were observed with different frequencies, 
the integration procedure yielded stable clusters with cells from 
both datasets. Briefly, raw counts were log-normalized separately, 
and the 10,000 most variable genes were identified by variance sta-
bilizing transformation for each dataset. The 4529 variable genes 
present in both datasets, and the first 30 PCs were used as features 
for identifying the integration anchors. The integrated expression 
matrix was scaled and dimensionality-reduced using PCA. On the 
basis of their percentage of explained variance, the first 28 PCs were 
chosen for UMAP visualization and clustering.
Graph-based clustering was performed using the Louvain algorithm 
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with Clustree on a range of resolution values (0.4 to 1.4), with 0.6 
yielding the most stable set of clusters (107). Overall, 26 clusters 
were identified, the smallest of which contained only 43 cells with 
gene expression patterns consistent with blood cells, which were ex-
cluded from further visualization plots. Clustering the two datasets 
separately yielded similar results. Moreover, the distribution of cells 
from each dataset across clusters was homogeneous (fig. S7), and 
the clusters corresponded to previous cell class and subtype annotations 
(50). As previously reported, a small cluster of excitatory neurons 
(cluster 13) contained neurons from the anterior olfactory nucleus. 
UMAP visualizations of expression level for cell class and cell-type 
markers, and for genes coding for coronavirus entry proteins, depict 
log-normalized UMI counts. The heatmap in Fig. 7C shows the mean 
expression level for each cell class, normalized to the maximum 
mean value. The percentage of cells per cell class expressing Ace2 
was defined as the percentage of cells with at least one UMI. In cells 
from both datasets, Ace2 was enriched in pericytes but was not de-
tected in neurons.
Smart-seq2 sequencing of manually sorted OB 
dopaminergic neurons
Tissue dissociation and manual cell sorting
Acute OB 300-m slices were obtained from Dat-Cre/Flox-tdTomato 
[B6.SJL-Slc6a3tm1.1(cre) Bkmn/J, JAX stock 006660/B6.Cg-Gt(ROSA) 
26Sortm9(CAG-tdTomato)Hze, JAX stock 007909] P28 mice as previously 
described (108). As part of a wider study, at P27, these mice had 
undergone brief 24-hour unilateral naris occlusion via a plastic plug 
insert (n = 5 mice) or were subjected to a sham control manipula-
tion (n = 5 mice); all observed effects here were independent of these 
treatment groups. Single-cell suspensions were generated using the 
Neural Tissue Dissociation Kit–Postnatal Neurons (Miltenyi Biotec, 
catalog no. 130-094-802), following the manufacturer’s instructions for 
manual dissociation, using three fired-polished Pasteur pipettes of 
progressively smaller diameter. After enzymatic and mechanical disso-
ciations, cells were filtered through a 30-m cell strainer, centrifuged 
for 10 min at 4°C, resuspended in 500 l of artificial cerebro-
spinal fluid (ACSF) (140 mM NaCl, 1.25 mM KCl, 1.25 mM NaH2PO4, 
10 mM Hepes, 25 mM glucose, 3 mM MgCl2, and 1 mM CaCl2) 
with channel blockers [0.1 M tetrodotoxin (TTX), 20 M 6-cyano- 7- 
nitroquinoxaline-2,3-dione (CNQX), and 50 M d-aminophosphovalerate 
(AP-V)], and kept on ice to minimize excitotoxicity and cell death.
For manual sorting of fluorescently labeled dopaminergic neurons, 
we adapted a previously described protocol (109). Fifty microliters 
of single-cell suspension was dispersed on 3.5-mm petri dishes 
(with a Sylgard-covered base) containing 2 ml of ACSF + channel 
blockers. Dishes were left undisturbed for 15 min to allow the cells 
to sink and settle. Throughout, dishes were kept on a metal plate on 
top of ice. tdTomato+ cells were identified by their red fluorescence 
under a stereoscope. Using a pulled glass capillary pipette attached 
to a mouthpiece, individual cells were aspirated and transferred to a 
clean, empty dish containing 2 ml of ACSF + channel blockers. The 
same cell was then transferred to a third clean plate, changing pipettes 
for every plate change. Last, each individual cell was transferred to a 
0.2-ml polymerase chain reaction (PCR) tube containing 2 l of 
lysis buffer (RLT Plus, QIAGEN). The tube was immediately placed 
on a metal plate sitting on top of dry ice for flash- freezing. Collected 
cells were stored at −80°C until further processing. Positive (more 
than 10 cells) and negative (sample collection procedure without 
picking a cell) controls were collected for each sorting session. In 
total, we collected samples from 10 mice, averaging 50 tdTomato+ 
cells collected per session. Overall, less than 2.5 hours elapsed be-
tween mouse sacrifice and collection of the last cell in any session.
Preparation and amplification of full-length cDNA  
and sequencing libraries
Samples were processed using a modified version of the Smart-seq2 
protocol (110). Briefly, 1 l of a 1:2,000,000 dilution of ERCC spike-
ins (Invitrogen, catalog no. 4456740) was added to each sample, and 
mRNA was captured using modified oligo (dT) biotinylated beads 
(Dynabeads, Invitrogen). PCR amplification was performed for 
22 cycles. Amplified cDNA was cleaned with a 0.8:1 ratio of Ampure- 
XP beads (Beckman Coulter). cDNAs were quantified on Qubit using 
HS DNA reagents (Invitrogen), and selected samples were run on a 
Bioanalyzer HS DNA chip (Agilent) to evaluate size distribution.
To generate the sequencing libraries, individual cDNA samples 
were normalized to 0.2 ng/l, and 1 l was used for one-quarter 
standard-sized Nextera XT (Illumina) tagmentation reactions, with 
12 amplification cycles. Sample indexing was performed using in-
dex sets A and D (Illumina). At this point, individual samples were 
pooled according to their index set. Pooled libraries were cleaned 
using a 0.6:1 ratio of Ampure beads and quantified on Qubit using 
HS DNA reagents and with the KAPA Library Quantification Kits 
for Illumina (Roche). Samples were sequenced on two separate rapid 
runs on HiSeq 2500 (Illumina), generating 100–base pair paired-end 
reads. An additional five samples were sequenced on MiSeq (Illumina).
Full-length cDNA sequencing data processing and analysis
Paired-end read fastq files were demultiplexed, quality-controlled 
using FastQC (www.bioinformatics.babraham.ac.uk/projects/fastqc/), 
and trimmed using Trim Galore (www.bioinformatics.babraham.
ac.uk/projects/trim_galore/). Reads were pseudo-aligned and quan-
tified using kallisto (111) against a reference transcriptome from 
Ensembl Release 89 (Gencode Release M17 GRCm38.p6) with sequences 
corresponding to the ERCC spike-ins and the Cre recombinase and 
tdT (tdTomato) genes added to the index. Transcripts were collapsed 
into genes using the sumAcrossFeatures function in scater.
Cell-level quality control and cell filtering were performed in scater 
(112). Cells with <1000 genes, <100,000 reads, >75% reads mapping 
to ERCC spike-ins, >10% reads mapping to mitochondrial genes, or 
low library complexity were discarded (14% samples). The popula-
tion of OB cells labeled in Dat-Cre/Flox-tdTomato mice is known to 
include a minor nondopaminergic calretinin+ subgroup (113), so 
calretinin-expressing cells were excluded from all analyses. The 
scTransform function in Seurat was used to remove technical batch 
effects.
Expression of CoV-relevant genes in scSeq datasets 
from various brain regions and sensory systems
An analysis of single-cell gene expression data from 10 studies was 
performed to investigate the expression of genes coding for coronavirus 
entry proteins in neurons from a range of brain regions and sensory 
systems. Processed gene expression data tables were obtained from 
scSeq studies that evaluated gene expression in retina (GSE81905) 
(114), inner ear sensory epithelium (GSE115934) (115, 116), spiral 
ganglion (GSE114997) (117), ventral midbrain (GSE76381) (118), 
hippocampus (GSE100449) (119), cortex (GSE107632) (120), hypo-
thalamus (GSE74672) (121), visceral motor neurons (GSE78845) 
(122), dorsal root ganglia (GSE59739) (123), and spinal cord dorsal 
horn (GSE103840) (124). Smart-seq2 sequencing data from Vsx2–
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dataset. A subset of the expression matrix that corresponds to day 0 
(i.e., control, undisturbed neurons) was used from the layer VI 
somatosensory cortex dataset. A subset of the data containing neurons 
from untreated (control) mice were used from the hypothalamic 
neuron dataset. From the ventral midbrain dopaminergic neuron 
dataset, a subset comprising DAT-Cre/tdTomato+ neurons from P28 
mice was used. A subset comprising type I neurons from wild-type 
mice was used from the spiral ganglion dataset. The “unclassified” 
neurons were excluded from the visceral motor neuron dataset. A 
subset containing neurons that were collected at room temperature 
was used from the dorsal root ganglia dataset. Expression data from 
dorsal horn neurons obtained from C57/BL6 wild-type mice and 
vGat-Cre-tdTomato and vGlut2-eGFP mouse lines were used from the 
spinal cord dataset. Inspection of all datasets for batch effects was 
performed using the scater package (version 1.10.1) (112). Publicly 
available raw count expression matrices were used for the retina, 
hippocampus, hypothalamus, midbrain, visceral motor neurons, and 
spinal cord datasets, whereas the normalized expression data were 
used from the inner ear hair cell datasets. For datasets containing raw 
counts, normalization was performed for each dataset separately by 
computing pool-based size factors that are subsequently decon-
volved to obtain cell-based size factors using the scran package 
(version 1.10.2) (125). Violin plots were generated in scater.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/31/eabc5801/DC1
View/request a protocol for this paper from Bio-protocol.
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